Related Experiment Videos
Clinical development of antisense oligonucleotides as anti-cancer therapeutics
1Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
Methods in Molecular Medicine
|November 1, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort.
Therapeutic advances in medical oncology·2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.
Journal of gynecologic oncology·2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.
Journal for immunotherapy of cancer·2026
Methods for cancer gene therapy using tumor suppressor genes.
Methods in molecular medicine·2014
Suppression of the human carcinoma phenotype by an antioncogene ribozyme.
Methods in molecular medicine·2014
Methods for the use of stromal cells for therapeutic gene therapy.
Methods in molecular medicine·2014
Methods for adenovirus-mediated gene transfer to synovium in vivo.
Methods in molecular medicine·2014
Methods for gene transfer to synovium.
Methods in molecular medicine·2014
Methods for generation of genetically modified fibroblasts for immunotherapy of cancer.
Methods in molecular medicine·2014